Immunotherapy in Myeloma : A Theme Issue in Honor of Prof. Dr. Gösta Gahrton

doi:10.3390/books978-3-0365-2907-3

Download Url(s)

https://mdpi.com/books/pdfview/book/4871

Contributor(s)

Kröger, Nicolaus (editor)

Garderet, Laurent (editor)

Language

English

Show full item record

Abstract

Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this hematological malignancy.

URI

https://directory.doabooks.org/handle/20.500.12854/78777

Keywords

multiple myeloma; immunotherapy; daratumumab; BCMA; bi-specific T cell engagers; chimeric antigen receptor; relapse; cytokine-release syndrome; allogeneic transplantation; myeloablative; non-myeloablative; new drugs; CAR T; antibodies; monoclonal; bispecific; immunoconjugates; antibody-drug conjugates; myeloma; NK cells; immunomodulation; cell therapy; graft-versus-myeloma; donor lymphocyte infusion; allogeneic stem cell transplantation; prophylaxis; salvage; CAR T-cells; target antigen; n/a